Corcept Therapeutics
CORT
135 hedge funds and large institutions have $665M invested in Corcept Therapeutics in 2017 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 37 increasing their positions, 52 reducing their positions, and 22 closing their positions.
779% more call options, than puts
Call options by funds: $1.97M | Put options by funds: $224K
72% more capital invested
Capital invested by funds: $387M → $665M (+$278M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 22
5.64% more ownership
Funds ownership: 48.05% → 53.69% (+5.6%)
0% more funds holding
Funds holding: 135 → 135 (0)
29% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$60.4M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$45.4M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.56M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.97M |
| 5 |
Bank of New York Mellon
New York
|
+$3.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
Investor AB
Stockholm,
Sweden
|
-$5.49M |
| 2 |
Two Sigma Investments
New York
|
-$3.78M |
| 3 |
Morgan Stanley
New York
|
-$2.98M |
| 4 |
ISL
Ingalls & Snyder LLC
New York
|
-$2.78M |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$1.8M |
CORT Hedge Fund Activity: Q1 2017 in Review
135 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2017, worth a combined $665M — up 72% from $387M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CORT positions and 22 closed out — a net gain of 6 holders — while 37 added to existing stakes and 52 trimmed.
The largest buyer was BlackRock, adding an estimated $60.4M. The largest seller was Investor AB, cutting an estimated $5.49M.
- 135 institutional investors held Corcept Therapeutics (CORT) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $665M of Corcept Therapeutics stock for Q1 2017, up 72% quarter-over-quarter.
- 28 funds opened new Corcept Therapeutics positions in Q1 2017 and 22 closed out, a net change of +6 holders.
- The largest Corcept Therapeutics buyer in Q1 2017 was BlackRock, an estimated $60.4M added.
- The largest Corcept Therapeutics seller in Q1 2017 was Investor AB, an estimated $5.49M sold.
Based on aggregated 13F filings for Q1 2017.